Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23913862 | 0.82 | MAPK1 (0.53) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL10066409 | 0.82 | MEN1 (0.54) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL10053477 | 0.81 | MEN1 (0.53) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL4833617 | 0.81 | MEN1 (0.53) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL29788840 | 0.81 | ALDH1A1 (0.65) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL2532477 | 0.80 | CYP19A1 (0.55) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL31422371 | 0.79 | KDM4E (0.50) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL9978689 | 0.78 | CYP19A1 (0.53) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL9584318 | 0.78 | KDM4E (0.49) | KDM4EMAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL6115563 | 0.78 | KCNJ1 (0.51) | KDM4EMAPK1L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845767-B2 | Arginase inhibitors | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-12-19 | — | — | US | disclosed |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-09-13 | — | — | US | disclosed |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-07-21 | — | — | US | disclosed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| EP-3383858-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| CN-108602795-A | The inhibitor of metal-beta-lactamase | 牛津大学科技创新有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105263914-B | biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | 艾尼纳制药公司 | 2017-10-27 | — | — | CN | disclosed |
| WO-2017093727-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
| EP-1395566-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096883-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | KDM4E 3237/4885MAPK1 1277/4885L3MBTL1 3159/4885 |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM4E 4094/4885MAPK1 343/4885L3MBTL1 4202/4885 |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | ARG1, ARG2, ARGLU1 | KDM4E 1686/4885MAPK1 1593/4885L3MBTL1 4661/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | KDM4E 4094/4885MAPK1 343/4885L3MBTL1 4202/4885 |
| US-11845767-B2 | Arginase inhibitors | ARG1, ARG2, ARGLU1 | KDM4E 1743/4885MAPK1 1598/4885L3MBTL1 4634/4885 |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | IDO1, MGAM, LCT | KDM4E 1800/4885MAPK1 4219/4885L3MBTL1 834/4885 |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | IDO1, MGAM, LCT | KDM4E 1800/4885MAPK1 4219/4885L3MBTL1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.